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Abstract
 
Few studies have demonstrated that innate lymphocytes play a major role in preventing sponta-
neous tumor formation. We evaluated the development of spontaneous tumors in mice lacking
 
 
 
-2 microglobulin (
 
 
 
2m; and thus MHC class I, CD1d, and CD16) and/or perforin, since
these tumor cells would be expected to activate innate effector cells. Approximately half the
cohort of perforin gene-targeted mice succumbed to spontaneous disseminated B cell lymphomas
and in mice that also lacked 
 
 
 
2m, the lymphomas developed earlier (by more than 100 d) and
with greater incidence (84%). B cell lymphomas from perforin/
 
 
 
2m gene-targeted mice effec-
tively primed cell-mediated cytotoxicity and perforin, but not IFN-
 
 
 
, IL-12, or IL-18, was
absolutely essential for tumor rejection. Activated NK1.1
 
 
 
 and 
 
  
 
TCR
 
 
 
 T cells were abundant
at the tumor site, and transplanted tumors were strongly rejected by either, or both, of these
cell types. Blockade of a number of different known costimulatory pathways failed to prevent
tumor rejection. These results reflect a critical role for NK cells and 
 
  
 
TCR
 
 
 
 T cells in innate
immune surveillance of B cell lymphomas, mediated by as yet undetermined pathway(s) of
tumor recognition.
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Introduction
 
Immune surveillance against tumors has been debated for
decades, although it has been well established using experi-
mental tumor cell lines in mAb-treated and gene-targeted
mice that the immune system recognizes and inhibits tumor
growth (1–8). More recently, interest has shifted to determine
whether the immune system can recognize precancerous
cells, thus preventing tumor development. Mice deficient
in key adaptive and innate immune effector molecules such
as perforin (pfp) and IFN-
 
 
 
 have illustrated the importance
of these molecules in tumor prevention in aging mice or
when predisposing factors such as chemical carcinogens or
loss of tumor suppressors drive carcinogenesis (5, 7, 9–11).
The lymphomas arising in pfp-deficient mice were of B cell
origin, extremely immunogenic, and all susceptible to
CD8
 
 
 
 T cell–mediated attack when transplanted into synge-
neic WT recipients (5). These data and others (12) supported
the important role adaptive immune responses play in
spontaneous tumor control.
The role of innate immune cells such as NK cells and
 
  
 
TCR
 
 
 
 T cells in immune surveillance of tumors remains
controversial. Both NK cells and 
 
  
 
TCR
 
 
 
 T cells express
perforin (13, 14), mediate spontaneous cytotoxicity, and
produce many antitumor cytokines such as IFN-
 
 
 
, when
they recognize target cells via one or more of several cell
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surface receptors (15, 16). NK cells can spontaneously kill
MHC class I–deficient tumor cell lines in vivo (1, 6) and
suppress experimental and spontaneous metastasis in mice,
but there are few models where NK cells or 
 
  
 
TCR
 
 
 
 T
cells prevent primary tumor formation (3, 17–19).
Mice gene targeted for 
 
 
 
2
 
-microglobulin (
 
 
 
2m) express
little or no cell surface MHC class I, CD1d, or CD16
(Fc
 
 
 
 receptor III; reference 20), have greatly diminished
CD8
 
  
 
T cell numbers, and lack CD1d-restricted T cells.
We investigated spontaneous tumor development in aging
 
 
 
2m-deficient mice compared with mice doubly deficient
in pfp and 
 
 
 
2m, to determine whether the latter mice
would develop lymphomas and additional tumors, and
whether innate effector cells, such as NK cells and
 
  
 
TCR
 
 
 
 T cells, could recognize and eliminate such tu-
mors given their lack of MHC class I molecules.
 
Materials and Methods
 
Mice.
 
Inbred C57BL/6 WT mice were purchased from The
Walter and Eliza Hall Institute of Medical Research (Melbourne,
Australia). The following gene-targeted mice were bred at the
Austin Research Institute Biological Research Laboratories
(ARI-BRL; Heidelberg, Australia) and at the Peter Mac (East
Melbourne, Australia): C57BL/6 perforin deficient (B6 pfp
 
 
 
/
 
 
 
);
C57BL/6 
 
 
 
-2-microglobulin deficient (B6 
 
 
 
2m
 
 
 
/
 
 
 
); and
C57BL/6 pfp
 
 
 
/
 
 
 
 
 
 
 
2m
 
 
 
/
 
 
 
 (21). All aging mice were bred, main-
tained, and monitored as described previously (5). Mean lifespan
(age of onset of lymphoma detected) 
 
 
 
 standard error of the
mean was calculated and probability of significance determined
using a Mann-Whitney Rank Sum U test. C57BL/6 RAG-1
 
 
 
/
 
 
 
(Animal Resources Centre, Canning Vale, Western Australia)
and C57BL/6 J
 
 
 
18
 
 
 
/
 
 
 
 (backcrossed to C57BL/6 for 12 genera-
tions and provided by Dr. M. Taniguchi, Chiba University,
Chiba, Japan) mice were bred and maintained at the Peter Mac.
Congenic Ly-5.1
 
 
 
 B6 mice were purchased from the Animal
Resources Centre and bred with B6 pfp
 
 
 
/
 
 
 
 mice to generate a
B6 Ly-5.1
 
 
 
pfp
 
 
 
/
 
 
 
 line. Mice 6–15 wk of age were used in trans-
plantation studies in accordance with the Peter Mac animal ex-
perimental ethics committee.
 
Flow Cytometry.
 
The following reagents used for flow cy-
tometry were purchased from BD Biosciences: anti–
 
  
 
TCR-
FITC or APC (H57–597); anti–NK1.1-PE (PK136); anti–Ly5.2-
FITC (104); and anti–
 
  
 
TCR-biotin or FITC (clone GL3).
Anti-Fc receptor (2.4G2) was used to prevent nonspecific bind-
ing by mAb. Intracellular staining was performed using the Cy-
toperm Kit (BD Biosciences) as per their instructions. Analysis
was performed on a FACScalibur
 
®
 
 using CellQuest software or
LSR II using FACsDIVA
 
®
 
 software (Becton Dickinson).
 
Tumor Transplantation Experiments.
 
Three representative (of
many) B cell lymphomas from B6 pfp
 
 
 
/
 
 
 
 
 
 
 
2m
 
 
 
/
 
 
 
 mice,
 
 
 
2mNPN-2, 
 
 
 
2mNPN-8, and 
 
 
 
2mNPN-10 (B220
 
 
 
Ig
 
 
 
TCR
 
  
 
 
 
) were transferred into WT, gene-targeted, and anti-
body-treated mice. Groups of three to five WT or gene-targeted
mice were injected i.p. with increasing numbers of lymphoma
cells and observed daily for tumor growth for over 150 d. Some
groups of WT and gene-targeted mice were depleted of NK1.1
 
 
 
,
asialo-GM1
 
 
 
, or 
 
  
 
TCR
 
 
 
 T cells in vivo by treatment with 200
 
 
 
g anti-NK1.1 mAb (PK136), rabbit anti–asialo-GM1 antibody
(Wako Chemicals), or anti-
 
  
 
TCR mAb (GL3), respectively,
on days 
 
 
 
2, 0 (day of tumor inoculation), and then either once
or twice a week to deplete subsets as described previously (6, 17,
22, 23).
 
Peritoneal Challenge and Peritoneal Exudate Lymphocytes (PEL)
Cytotoxicity.
 
The number of cells migrating to the peritoneum
was evaluated as described previously (2) in groups of five B6
WT, pfp
 
 
 
/
 
 
 
, or RAG-1
 
 
 
/
 
 
 
 mice that had received PBS or tumor
cells (10
 
4
 
)/0.2 ml i.p. as indicated. Some groups of B6 WT mice
were pretreated with 200 
 
 
 
g of one or both of anti-NK1.1
(PK136) and anti-
 
  
 
TCR (GL3). Peritoneal contents were ana-
lyzed for proportions of NK1.1
 
 
 
, 
 
  
 
TCR
 
 
 
, and other leuko-
cytes by flow cytometry as above. The cytolytic activity of the
PEL was measured against a series of different target cells (as indi-
cated) at various effector/target ratios using a 4-h 
 
51
 
Cr release as-
say as described previously (2).
 
Online Supplemental Material.
 
Figs. S1–S4 and associated
methods are available at http://www.jem.org/cgi/content/full/
jem.20031981/DC1.
 
Results and Discussion
 
Spontaneous B Cell Lymphomas Develop in 
 
 
 
2m
 
 
 
/
 
 
 
 pfp
 
 
 
/
 
 
 
Mice.
 
We undertook to monitor spontaneous tumor de-
velopment in WT C57BL/6 (B6) or those that were defi-
cient in 
 
 
 
2m and/or pfp. B6 pfp
 
 
 
/
 
 
 
 mice died from aggres-
sive disseminated lymphomas affecting the spleen, liver, and
lymph nodes from 300 d onwards, with 57% (12/21) suc-
cumbing by the end of the experiment [mean lifespan 
 
 
 
495 
 
 
 
 35 d] (Fig. 1). B6 pfp
 
 
 
/
 
 
 
 
 
 
 
2m
 
 /  mice developed
more disseminated lymphomas (27/32, 84%) and statistically
earlier onset (mean lifespan 387   24 d, P   0.0136). No
other tumor types were detected and WT B6 mice (0/39
mice) and mice deficient in  2m (0/21) did not develop
any tumors over the same observation period (Fig. 1). The
reduced incidence and later onset of lymphomas in B6 pfp / 
mice suggested that in these mice additional nonperforin
effector mechanisms mediated by a  2m-dependent recog-
nition process (e.g., by CD8  T cells or CD1d-restricted
NKT cells) might compensate for the loss of pfp. The NK
cell compartment of B6 pfp /   2m /  mice is somewhat
“anergic” in response to MHC class I–deficient tumors or
cells (21, 24) and this may also explain the earlier onset and
greater incidence of lymphoma in these mice. As described
previously, all of the disseminated lymphomas in B6 pfp / 
mice were of B cell origin (B220  sIg  CD4  CD8 
TCR ), or less frequently, plasmacytomas (B220  CD4 
CD8  TCR  sIglow and histological appearance) (10). All
the disseminated lymphomas from B6 pfp /   2m /  mice
were also of B cell origin (B220  sIg  CD4  CD8  TCR ;
Fig. S1). In contrast to the high level of MHC class I ex-
pressed by lymphomas emerging in B6 pfp /  mice (5, 10),
those arising in B6 pfp /   2m /  mice expressed I-Ab, but
lacked H-2Kb, H-2Db, and CD1d (Fig. S1).
Both NK Cells and   TCR  T Cells Reject B Cell Lym-
phoma in pfp-dependent Manner. The primary B cell lym-
phomas arising in B6 pfp /    2m /  mice grew in B6
pfp /  mice at doses as low as 104 cells, but not in WT mice
at 107 cells (Fig. 2 a). By contrast, mice deficient for one or
more of TRAIL, TNF, or FasL rejected 107 tumor cells
(Fig. S2), indicating that pfp was the major cytotoxic effec-Street et al. Brief Definitive Report 881
tor mechanism used in tumor rejection. Mice deficient in
IFN- , IL-12, and/or IL-18 also rejected these lymphomas,
demonstrating that secretion of these cytokines by NK cells
or antigen-presenting cells was not critical for tumor rejec-
tion (Fig. S2). To establish the effector cell population(s) re-
quired for B cell lymphoma rejection, each lymphoma was
transferred at 107 cells into a variety of gene-targeted, mu-
tant, or lymphocyte subset–depleted mice (Fig. 2 b and Fig.
S2). RAG-1 /  and other T cell–deficient mice rejected B
cell lymphomas from B6 pfp /   2m /  mice, as did non-
obese diabetic (NOD) scid mice that lack T cells and have a
partial defect in NK cell effector functions (25; and Fig. S2).
Only RAG-1 /  mice depleted of NK1.1  (NK) cells or
WT mice depleted of both NK1.1  cells and   TCR  T
cells succumbed to lymphoma (Fig. 2 b). Importantly,
J 18 /  mice (deficient in NKT cells) alone or additionally
depleted of NK1.1  cells also rejected the lymphomas, fur-
ther proving that NKT cells were not critical for tumor re-
jection (Fig. 2 b). Mice depleted of NK cells or   TCR  T
cells alone did not develop lymphomas, consistent with the
ability of each subset to mediate tumor rejection in the ab-
sence of the other (Fig. 2 b). In concert with our previous
data (5, 10), all MHC class I–expressing B cell lymphomas
from B6 pfp /  mice grew in B6 pfp /  mice, but were av-
idly rejected when transferred into B6 WT mice by CD8 
T cells (unpublished results).
B Cell Lymphomas Prime NK Cell and    T Cell Activa-
tion In Vivo. To specifically examine the response of NK
cells and     T cells to B cell lymphomas, we transplanted
Ly-5.2   2mNPN-8 from B6 pfp /   2m /  mice into
B6.Ly-5.1 pfp /  mice. 21 d later the cellularity of tumor-
burdened spleens was 10–50-fold greater than control B6
mice (unpublished data), with a general increase in most
populations (other than B cells), whereas B220 Ly5.2 
cells (2.5%) defined the tumor burden of the B6.Ly-
5.1 pfp /  mice (Fig. 3 a). By cell surface labeling there
was no specific increase in the proportion of NK1.1  or
  TCR T cells in lymphoma-burdened mice (Fig. 3 a),
although an increase in the proportion of NK1.1 B220 
cells (0.40 to 1.58%) was noted. Consistent with internal-
ization of TCR and NK cell receptors upon activation (26,
27), intracellular staining revealed an approximately eight-
fold and two- to threefold increase in the proportions of
  TCR  and NK1.1  cells, respectively, in lymphoma-
burdened mice compared with control mice (Fig. 3 b), and
thus represented a tremendous increase in the number of
  TCR T cells and NK1.1  cells in lymphoma-inocu-
lated mice. The specific internalization of   TCR and
NK1.1 antigens suggested that these cells were being spe-
cifically stimulated by the presence of the B cell lymphoma,
whereas   TCR  T cells were increased in number, but
not proportion, and their TCR had not been internalized.
The accumulation of NK1.1  and   TCR  cells was fur-
ther confirmed by their detection around masses of B220 
(and Ly-5.2 ) tumor cells (Fig. S3).
Consistent with previous observations after intraperitoneal
challenge with MHC class I–deficient RMA-S tumor cells
(2, 28), after 72 h cell number in the peritoneum was en-
hanced three- to fourfold in all mice inoculated with any of
the B cell lymphomas (unpublished data). Importantly, PEL
Figure 1. Perforin protects mice from spontaneous B cell lymphomas.
Groups of mice (number in square brackets) were evaluated twice weekly
and when moribund, a full autopsy was performed and tumor type recorded
against time of sacrifice. The lifespan of each pfp /  and  2m / pfp / 
mouse developing a disseminated lymphoma is depicted by a symbol and
the total number succumbing shown in round brackets. The lifespan
(detected age of onset of lymphoma) of the  2m / pfp /  mice was sig-
nificantly reduced when compared with that of pfp /  mice (P   0.0136,
Mann-Whitney).
Figure 2. Spontaneous lymphomas arising in  2m / pfp /   were
malignant and rejected by NK and    T cells. Groups of five B6 WT and
gene-targeted mice were inoculated i.p. with primary lymphomas arising
in B6 pfp /    2m /  mice. Some groups of mice were depleted of
NK1.1  or   TCR  cells using Ab or a hamster isotype Ig control as
indicated. Transplant of  2mNPN-8 lymphoma cells (104 to 107 cells in
0.2 ml PBS) is representative of all the lymphomas transferred. Individual
tumor-free mice remaining after 150 d are represented right of the inserted
vertical line and are represented by each symbol. (a) Pfp /  mice were at
least 1,000-fold more susceptible to  2mNPN-8 lymphoma than WT
mice. (b) Either NK cells and/or    T cells mediated lymphoma rejection.Tumor Immunosurveillance Effected by NK and    T Cells 882
that had been primed by RMA-S or  2mNPN-8 tumor
challenge were capable of rapid lysis of either Yac-1 or
 2mNPN-8 tumor targets (Fig. 4 a). By contrast, RMA tu-
mor challenge did not stimulate PEL cytotoxicity against
Yac-1 or  2mNPN-8 tumor cells and PEL from PBS-inoc-
ulated B6 WT mice were only weakly lytic toward
 2mNPN-8 and NK cell–sensitive Yac-1 target cells (Fig. 4
a). In addition, freshly isolated spleen mononuclear cells did
not significantly lyse  2mNPN-8 tumor cells in 4 or 16 h
cytotoxicity assays (unpublished data). PEL from RAG-1 / 
mice that had been primed by  2mNPN-8 tumor challenge
were capable of rapid lysis of either Yac-1 (Fig. 4 b) or
 2mNPN-8 tumor targets (unpublished data). By contrast,
despite effective cellular recruitment in pfp /  mice (unpub-
lished data), PEL from pfp /  mice that had been primed by
 2mNPN-8 tumor challenge were incapable of lysing either
Yac-1 (Fig. 4 b) or  2mNPN-8 tumor targets (unpublished
data). Furthermore, PEL from  2mNPN-8–primed pfp / ,
RAG-1 / , or WT mice depleted of NK1.1  cells were un-
able to lyse Yac-1 (Fig. 4 c) or  2mNPN-8 target cells (un-
published data). PEL from  2mNPN-8–primed WT mice
depleted of   TCR  cells were somewhat reduced in their
specific ability to lyse Yac-1 (Fig. 4 c). Although NK cells
were activated and did mediate enhanced perforin-depen-
dent cytotoxicity against these tumor cells and Yac-1 after
priming in vivo, the relatively minor role of   TCR T cells
in mediating cytotoxicity in this assay may not necessarily
correlate with their activation and role in tumor rejection.
A Novel Mechanism of Tumor Recognition by NK Cells and
  TCR  T Cells? All B cell lymphomas arising in B6
pfp /   2m /  mice expressed abundant levels of CD40,
CD48, CD70, CD80, and CD86, low levels of NKG2D
ligands, and 4–1BBL, but not ICOSL or OX40L (Fig. S4
a). PEL from RAG-1 /  mice that had been primed by
 2mNPN-8 tumor challenge remained capable of lysis of
either Yac-1 (Fig. S4 b) or  2mNPN-8 tumor targets (un-
published data), even when mice had been pretreated with
either a cocktail of neutralizing mAbs to CD40L, CD70,
CD80, and CD86 or anti-NKG2D alone. Single or collec-
tive inhibition of the NKG2D/NKG2D ligand, CD40L/
CD40, CD27/CD70, CD28/CD80, CD28/CD86, CD48/
CD2, and CD48/2B4 costimulatory pathways did not pre-
vent lymphoma rejection (Fig. S4 c). As NK cell and    T
cell activation may require the simultaneous engagement
of stimulatory and costimulatory receptors, it remains to be
Figure 3. B cell lymphomas induce NK cell and    T cell accumulation
in vivo. (a)  2mNPN-2 (Ly5.2 ) lymphoma cells (107) were trans-
planted into B6.Ly-5.1 pfp /  mice and 21 d later B220 , NK1.1 ,
  TCR , and   TCR  populations in tumor-burdened spleens were
compared with the spleens of control B6 (Ly5.2 ) mice by flow cytometry
as indicated. B220 Ly5.2  cells define the lymphoma amongst spleen
cells of the B6.Ly-5.1 pfp /  mice. (b) Spleen cells prepared in a similar
manner to panel a were permeabilized and stained intracellularly. Isotype
controls are included.
Figure 4. B cell lymphomas prime NK cell–mediated cytotoxicity.
(a)  2mNPN-8 lymphoma cells (104) were injected into the peritoneum
of groups of 5 B6 pfp /  mice, B6 WT mice, or WT mice depleted of
NK1.1  cells as indicated. As controls some groups of mice were challenged
with either PBS, MHC class I-deficient RMA-S (104) or parental RMA
(104) tumor cells. After 72 h, the cytotoxic potential of PEL was assessed
in a 4-h 51Cr release assay against Yac-1 or  2mNPN-8 target cells. Results
were recorded as the mean   SEM of triplicate samples and are representative
of three experiments. (b) The cytotoxic potential of PEL from WT,
RAG-1 / , or pfp /  mice primed by  2mNPN-8 tumor challenge (as
in A) was assessed in a 4-h 51Cr release assay against Yac-1 target cells.
Some groups of mice were pretreated with anti-NK1.1 mAb (100  g
each on days  1 and 1). (c) The cytotoxic potential of PEL from WT
mice primed by PBS,  2mNPN-8, or RMA-S tumor challenge (as in a)
was assessed in a 4-h 51Cr release assay against Yac-1 target cells. Some
groups of mice were pretreated with anti-NK1.1 or anti-  TCR mAb
(100  g each on days  1 and 1). Results were recorded as the mean   SEM
of triplicate samples and are representative of two experiments performed.Street et al. Brief Definitive Report 883
demonstrated which receptor(s) present the primary signal
to these effector cells.
Conclusions. Evidence for a primary role for NK cells
and   TCR T cells in tumor immune surveillance has re-
mained scant (17, 19). 40 yr ago Hodgkin’s-like B lympho-
mas spontaneously arising in aging C57L mice (25% inci-
dence at 21 mo of age), were first reported, but only
recently were these B cell lymphomas shown to express co-
stimulatory molecules and be controlled by NK cells in
syngeneic mice (29). Another study demonstrated that B
cell lymphomas arose with higher frequency in Fas mutant
lpr mice that were additionally deficient in    T cells or
   T cells (30). These experiments were performed on a
mixed C57BL/6/MRL background, but suggested that
   T cells contribute to the suppression of spontaneously
arising B cell lymphomas. Herein, we have directly illus-
trated in a syngeneic C57BL/6 background an incredibly
potent NK cell and    T cell response capable of rejecting
spontaneously arising MHC class I–deficient B cell lym-
phomas.   TCR T cells were shown in great numbers
around B cell tumor masses in the spleens of B6 pfp / 
mice. Such a response of   TCR T cells has not been
documented in previous disease models and most often
  TCR T cells have been shown to inhibit tumors initi-
ated in regions rich in   TCR-expressing intraepithelial
lymphocytes such as skin epidermis and gut (19, 31, 32). In
addition, the fact that these effector T cells internalized
  TCR suggests that these cells were activated via their
TCR and highlights that such activated   TCR T cells
might be missed if investigators only used staining for sur-
face TCR. A recent study described the ability of
  TCR T cells to provide an early source of IFN-  in
immune responses to carcinogen (33). Here we have
shown that the cytotoxic function of   TCR T cells may
also contribute to tumor rejection.
NK cells and   TCR  T cells potentially use a combi-
nation of receptors to detect stressed or transformed tumor
cells and may recognize tumors directly with no require-
ment for antigen processing or presentation. In the past 5 yr
we have begun to appreciate the activation receptors ex-
pressed by innate effector cells, such as NK cells and
  TCR T cells (28, 34). Although these B cell lympho-
mas expressed abundant levels of the costimulatory mole-
cules CD40, CD48, CD70, CD80, and CD86, but lacked
NKG2D ligands, blockade of each or several of these path-
ways also failed to prevent tumor rejection. Although the B
cell lymphomas may directly or indirectly stimulate NK
cells and    T cells by a soluble mediator, our preliminary
analysis of candidate cytokines such as IL-12, IL-18, IFN- ,
and TNF does not support such a contention. Collectively,
these data suggest the presence of another, as yet unrecog-
nized, activation receptor that exists on either NK cells or
  TCR T cells, or both cell types, and promotes perforin-
mediated cytotoxicity. This putative receptor does not rec-
ognize a  2m-dependent ligand, further suggesting novel
receptor/ligand pairs of biological significance remain to be
discovered using this tumor model.
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